Acetate → Bupropion

HRID 1991441Notes

Reaction equation

[CH3:1][CH:2]([NH:12][C:13]([CH3:16])([CH3:15])[CH3:14])[C:3]([C:5]1[CH:6]=[CH:7][CH:8]=[C:9]([Cl:11])[CH:10]=1)=[O:4].Cl.C([O-])(=O)C.P([O-])([O-])([O-])=O>>[CH3:1][CH:2]([NH:12][C:13]([CH3:14])([CH3:16])[CH3:15])[C:3]([C:5]1[CH:6]=[CH:7][CH:8]=[C:9]([Cl:11])[CH:10]=1)=[O:4]

Participants

Reactant 3

HCID 175Acetate

HCID 1061Phosphate

HCID 62884Bupropion Hydrochloride2×

Product 1

HCID 444Bupropion

Procedure

Also, FIG. 68 contains comparative dissolution profiles for Bupropion HBr XL 348 mg final, Wellbutrin XL EC, tablets in different USP-3 media (SGF pH 1.2, acetate buffer pH 4.5 and phosphate buffer pH 6.8) compared against in-vivo data for Bupropion HCl 150 mg XL target (Lot 02A063) over a period of 16 hours.

Sources & evidence

ORD record: ord-80ef9f74c1f241a3a774b821b931b595
Source dataset: uspto-grants-2010_01
DOI: 10.6084/m9.figshare.5104873.v1
Patent number: US07645802B2

Reaction notes

Loading…